Treatment Information

Back

Kidney (Renal) Cancer treatment details. Immunotherapy.

Beth Israel Deaconess Medical Center, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:ImmunotherapyHospital:Beth Israel Deaconess Medical Center
Drugs:Journal:Link
Date:Jan 2005

Description:

Patients: This Phase III study involved a total of 192 patients with metastatic renal cell carcinoma. Patients were divided into two groups of 96 patients each. Each group was administered a different therapy.

Treatment: For Group A, the treatment consisted of high-dose interleukin-2 (IL-2). For Group B, the treatment consisted of subcutaneous IL-2 plus interferon.

Toxicities: Grade 3 and 4 toxicities for group B iincluded: constitutional, hypotension gastrointestinal, hematologic, neurologic, cardiac, pulmonary, renal/electrolytes, psychiatric, hepatic, and infection.

Results: Median survival was 13 months for Group B.

Support: Several of the study's authors have acted as consultants, performed contract work for, or received more than $2,000/year from Chiron or Schering. Chiron markets IL-2. Schering markets interferon.

Correspondence: David F. McDermott, MD



Back